Prime Medicine Inc (PRME)
5.62
-0.10
(-1.75%)
USD |
NASDAQ |
May 10, 16:00
5.62
0.00 (0.00%)
After-Hours: 19:19
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 674.56M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -59.26% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 5.069 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology. |
URL | https://www.primemedicine.com |
Investor Relations URL | https://investors.primemedicine.com/ |
HQ State/Province | Massachusetts |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | May. 10, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology. |
URL | https://www.primemedicine.com |
Investor Relations URL | https://investors.primemedicine.com/ |
HQ State/Province | Massachusetts |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | N/A |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | May. 10, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |